Most Read Articles
01 Dec 2020
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Dr. Hsu Li Yang, Dr. Tan Thuan Tong, Dr. Andrea Kwa, 08 Jan 2021
Antimicrobial resistance has become increasingly dire as the rapid emergence of drug resistance, especially gram-negative pathogens, has outpaced the development of new antibiotics. At a recent virtual symposium, Dr Hsu Li Yang, Vice Dean (Global Health) and Programme Leader (Infectious Diseases), NUS Saw Swee Hock School of Public Health, presented epidemiological data on multidrug-resistant (MDR) gram-negative bacteria (GNB) in Asia, while Dr Tan Thuan Tong, Head and Senior Consultant, Department of Infectious Diseases, Singapore General Hospital (SGH), focused on the role of ceftazidime-avibactam in MDR GNB infections. Dr Andrea Kwa, Assistant Director of Research, Department of Pharmacy, SGH, joined the panel in an interactive fireside chat, to discuss challenges, practical considerations, and solutions in MDR gram-negative infections. This Pfizer-sponsored symposium was chaired by Dr Ng Shin Yi, Head and Senior Consultant of Surgical Intensive Care, SGH.
Tristan Manalac, Yesterday
While antibody titres against SARS-CoV-2 wane with time, the immune system is capable of producing memory B-cells that can last for at least 6 months after infection, suggesting that the body will be able to protect itself in the case of re-exposure, according to a new study.
Jairia Dela Cruz, 5 days ago
Spending too much time sitting cannot be good for the body, and rising to one's feet breaks up such a behaviour and yields small, but meaningful, reductions in certain cardiovascular disease (CVD) risk factors, according to the results of a meta-analysis.

Pitavastatin better for dyslipidaemia control in T2DM patients with LEAD

27 Dec 2020

Both pitavastatin and atorvastatin effectively reduce femoral total plaque area (FTPA) in type 2 diabetes mellitus (T2DM) patients with lower extremity atherosclerotic disease (LEAD), a new study has found. On the other hand, pitavastatin leads to better levels of high-density lipoprotein cholesterol (HDL-C).

The study included 63 T2DM patients with LEAD and elevated levels of low-density lipoprotein cholesterol (LDL-C). Participants were randomly assigned to receive either 2 mg/d of pitavastatin (n=28) or 10 mg/d of atorvastatin (n=35). Treatment lasted for 48 weeks. The primary outcome, FTPA, was assessed through ultrasonography.

Both treatment arms saw significant and sustained reductions in LDL-C and FTPA. Those in the pitavastatin group saw a mean FTPA drop of 13.63±15.27 mm2, while their atorvastatin comparators had an average reduction of 12.93±14.67 mm2. The percentage of patients experiencing FTPA regression was 78.6 percent and 80.0 percent in the respective groups, and the overall treatment efficiency was 79.4 percent.

Both treatments likewise resulted in increasing HDL-C, though pitavastatin had a significantly stronger effect than atorvastatin (final HDL-C concentrations: 1.32±0.23 vs 1.22±0.26 mmol/L; p<0.05).

Both treatments likewise led to improvements in levels of triglycerides and total cholesterol, as well as glycated haemoglobin, fasting plasma glucose, standard deviation of blood glucose, and coefficient of variation of fasting blood glucose. No significant between-arm differences were observed for these measures.

“[W]e proposed that pitavastatin may be superior in the control of dyslipidaemia in diabetic patients with LEAD,” the researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
01 Dec 2020
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Dr. Hsu Li Yang, Dr. Tan Thuan Tong, Dr. Andrea Kwa, 08 Jan 2021
Antimicrobial resistance has become increasingly dire as the rapid emergence of drug resistance, especially gram-negative pathogens, has outpaced the development of new antibiotics. At a recent virtual symposium, Dr Hsu Li Yang, Vice Dean (Global Health) and Programme Leader (Infectious Diseases), NUS Saw Swee Hock School of Public Health, presented epidemiological data on multidrug-resistant (MDR) gram-negative bacteria (GNB) in Asia, while Dr Tan Thuan Tong, Head and Senior Consultant, Department of Infectious Diseases, Singapore General Hospital (SGH), focused on the role of ceftazidime-avibactam in MDR GNB infections. Dr Andrea Kwa, Assistant Director of Research, Department of Pharmacy, SGH, joined the panel in an interactive fireside chat, to discuss challenges, practical considerations, and solutions in MDR gram-negative infections. This Pfizer-sponsored symposium was chaired by Dr Ng Shin Yi, Head and Senior Consultant of Surgical Intensive Care, SGH.
Tristan Manalac, Yesterday
While antibody titres against SARS-CoV-2 wane with time, the immune system is capable of producing memory B-cells that can last for at least 6 months after infection, suggesting that the body will be able to protect itself in the case of re-exposure, according to a new study.
Jairia Dela Cruz, 5 days ago
Spending too much time sitting cannot be good for the body, and rising to one's feet breaks up such a behaviour and yields small, but meaningful, reductions in certain cardiovascular disease (CVD) risk factors, according to the results of a meta-analysis.